Presidential decree amends Drugs Act to permit methylphenidate for ADHD treatment

President Dr. Mohamed Muizzu has issued a resolution to amend the Narcotics Act to make methylphenidate, a first-line treatment drug for people with Attention Deficit Hyperactivity Disorder (ADHD), available from Tuesday.

The President issued the resolution in accordance with Articles 3–4(e) of the Narcotic Drugs Act.

With this amendment, methylphenidate, which is used to treat people with ADHD, will be made available in the country within the legal framework. The change was made under Presidential Decree No. 10/2026, amending Schedule One of the Drugs Act. The decision was taken after the Cabinet discussed the recommendation of the National Drug Control Council.

To make the drug available, he sought Parliamentary approval under the Narcotic Drugs Act, which approved the removal of methylphenidate from the list of prohibited drugs listed in Schedule I of the Act. The approval was passed at the 17th session of the first session of Parliament held on 11 May 2026.

This change is expected to significantly ease the difficulties faced by those seeking treatment for ADHD.